BETTER-BP: Offering Cash Incentives Improves Anti-Hypertensive Medication Adherence, But Not Blood Pressure Control
Key Points: Adherence to antihypertensive medications remains a persistent challenge in clinical practice. The BETTER-BP trial randomized participants with poorly... Read more.
OCEAN: Ongoing Anticoagulation May Not be Necessary After 1-year Post Successful AF Ablation
Key Points: Atrial fibrillation (AF) increases the risk of stroke, and long-term oral anticoagulation is generally recommended for patients with atrial fibrillation... Read more.
VESALIUS-CV: PCSK9-Inhibitor Evolocumab Reduces MACE for Primary Prevention
Key Points: PCSK9-inhibitors – including evolocumab – are highly effective LDL-C–lowering medications that reduce major adverse cardiovascular events (MACE)... Read more.
DR10624, a First-in-Class FGF21/GLUCAGON/GLP-1 Receptor Triple Agonist, Significantly REDUCED Triglycerides, Lipids, and Liver Fat in Patients with Severe HYPERTRIGLYCERIDEMIA
Key Points: DR10624 is a first-in-class triple agonist of the FGF21, glucagon, and GLP-1 receptors, designed to improve metabolic parameters in patients with severe... Read more.
NEWTON-CABG: Evolocumab Did Not Improve Vein Graft Patency After CABG
Key Points: Saphenous vein graft (SVG) failure is common after coronary artery bypass grafting (CABG), with an occlusion rates of 20% within the first year after... Read more.
Essence-TIMI 73b: Olezarsen Safely and Effectively Reduces Triglycerides in Patients With Moderate Hypertriglyceridemia and High CV Risk
Key Points: Olezarsen, an anti-sense oligonucleotide targeting APOC3 mRNA, is approved to lower triglycerides (TG) in adults with rare familial chylomicronemia,... Read more.
VICTOR: Vericiguat Did Not Meet Primary Endpoint But Reduced CV Death in Stable, Ambulatory HFrEF
Key Points: The VICOTRIA trial previously demonstrated that vericiguat reduced the risk of heart failure (HF) hospitalization or cardiovascular (CV) death in patients... Read more.
VICTOR + VICTORIA: Vericiguat Showed Benefits Across the Spectrum of HFrEF Severity
Key Points: VICTORIA and VICTOR and were randomized trials that evaluated vericiguat versus placebo in HFrEF patients with and without recent decompensation, respectively.... Read more.
SUMMIT: Tirzepatide Improved Renal Function in Patients with HFpEF, Obesity, and CKD
Key Points The SUMMIT randomized control trial demonstrated that tirzepatide significantly reduced worsening heart failure events among patients with HFpEF and obesity... Read more.
EKSTROM Trial: Low-dose Colchicine Reduced Total Plaque Volume on CCTA, but Not Low Attenuation Plaque
Key Points The COLCOT trial demonstrated colchicine improved coronary plaque characteristics in patients with acute coronary syndrome compared with placebo. EKSTROM... Read more.